Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Japan
alvocidib
clinical trial
leukemia, myeloid
safety
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
27
05
2022
received:
04
01
2022
accepted:
06
06
2022
pubmed:
12
6
2022
medline:
15
12
2022
entrez:
11
6
2022
Statut:
ppublish
Résumé
Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment-refractory (R/R) AML or newly diagnosed patients with poor prognostic factors. Alvocidib (DSP-2033), a potent cyclin-dependent kinase 9 inhibitor, has previously demonstrated promising clinical activity for the treatment of AML. In this multicenter, open-label, uncontrolled, 3 + 3 phase I study, we investigated the safety and tolerability of alvocidib administered in combination with either cytarabine and mitoxantrone (ACM) for R/R AML or cytarabine/daunorubicin (A + 7 + 3) for newly diagnosed AML. Alvocidib was administered to all patients as a 30-min intravenous (i.v.) bolus (30 mg/m
Identifiants
pubmed: 35689544
doi: 10.1111/cas.15458
pmc: PMC9746059
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Daunorubicin
ZS7284E0ZP
Banques de données
ClinicalTrials.gov
['NCT03563560']
Types de publication
Multicenter Study
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4258-4266Subventions
Organisme : Sumitomo Pharma
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Haematologica. 2010 Jul;95(7):1098-105
pubmed: 20460644
Oncotarget. 2015 Feb 20;6(5):2667-79
pubmed: 25596730
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Jpn J Clin Oncol. 2016 Apr;46(4):394
pubmed: 27004901
Haematologica. 2015 Sep;100(9):1172-9
pubmed: 26022709
Clin Cancer Res. 2021 Jan 1;27(1):60-69
pubmed: 32998965
Blood Rev. 2020 Nov;44:100672
pubmed: 32204955
Carcinogenesis. 2019 Jul 4;40(5):651-660
pubmed: 30715157
EMBO J. 2008 Jul 9;27(13):1907-18
pubmed: 18566585
Ann Hematol. 2018 Jul;97(7):1115-1153
pubmed: 29680875
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood Cancer J. 2021 Oct 30;11(10):175
pubmed: 34718324
Haematologica. 2008 Jan;93(1):67-74
pubmed: 18166787
Cancer Sci. 2022 Dec;113(12):4258-4266
pubmed: 35689544
J Oncol. 2017;2017:9684909
pubmed: 29230244
Blood. 1997 Jan 15;89(2):630-43
pubmed: 9002967